These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 7657266)

  • 1. Ursodeoxycholic acid for chronic hepatitis C patients.
    Puoti C; Magrini A; Annovazzi G; Pannullo A; Filippi T
    Hepatology; 1995 Sep; 22(3):1002. PubMed ID: 7657266
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease.
    Puoti C; Magrini A; Filippi T; Annovazzi G; Pannullo A
    Eur J Gastroenterol Hepatol; 1995 Feb; 7(2):151-4. PubMed ID: 7712308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Use of ursodeoxycholic acid in treatment of chronic hepatitis C].
    Warunek W; Zejc-Bajsarowicz M; Librant-Suska M
    Folia Med Cracov; 1996; 37(1-2):97-100. PubMed ID: 9312530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ursodeoxycholic acid and chronic hepatitis C infection.
    Puoti C; Pannullo A; Annovazzi G; Filippi T; Magrini A
    Lancet; 1993 May; 341(8857):1413-4. PubMed ID: 8098817
    [No Abstract]   [Full Text] [Related]  

  • 6. [Features and therapy of the patients with chronic hepatitis C resistant to IFN therapy].
    Imazeki F; Yokosuka O; Omata M
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):1017-21. PubMed ID: 7563659
    [No Abstract]   [Full Text] [Related]  

  • 7. [Peripheral blood lymphocyte apoptosis in children with viral hepatites A, B, C and effect of ursodeoxycholic acid preparations].
    Matanina NV; Reĭzis AR
    Eksp Klin Gastroenterol; 2008; (5):106-10. PubMed ID: 19145924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study.
    Cadranel JF; Di Martino V; Dorent R; Bernard B; Hoang C; Myara A; Pauwels A; Ghoussoub JJ; Perrin M; Grippon P; Thabut D; Trivin F; Huraux JM; Gandjbakhch I; Opolon P; Lunel F
    Transplantation; 2003 Apr; 75(7):977-82. PubMed ID: 12698083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis C and 'normal' ALT levels: treat the disease not the test.
    Puoti C; Bellis L; Martellino F; Guarisco R; Dell' Unto O; Durola L; Galossi A
    J Hepatol; 2005 Sep; 43(3):534-5. PubMed ID: 16023245
    [No Abstract]   [Full Text] [Related]  

  • 10. Clearance of hepatitis C viral RNA in cirrhotic patients with antiviral therapy.
    Ono SK; da Silva LC; Carrilho FJ; da Fonseca LE; Mendes LC; Madruga CL; Farias Ade Q; Laudanna AA
    Rev Hosp Clin Fac Med Sao Paulo; 1996; 51(5):180-3. PubMed ID: 9216095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid therapy in recurrent or acquired genotype II hepatitis C virus infection after liver transplantation: a three-case report.
    Kita Y; Beck Y; Teraoka S; Yokota K; Andoh Y; Nagao T; Gotoh M; Sakon M; Monden M
    Transplant Proc; 1996 Jun; 28(3):1701-3. PubMed ID: 8658847
    [No Abstract]   [Full Text] [Related]  

  • 13. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels.
    Alberti A
    J Hepatol; 2005 Feb; 42(2):266-74. PubMed ID: 15664254
    [No Abstract]   [Full Text] [Related]  

  • 14. Thalidomide-induced normalization of serum ALT levels in a patient with hepatitis C.
    Raufman JP; Lamps LW
    Am J Gastroenterol; 2001 Nov; 96(11):3209-11. PubMed ID: 11721782
    [No Abstract]   [Full Text] [Related]  

  • 15. The chronic disease of childhood obesity: the sleeping giant has awakened.
    Sokol RJ
    J Pediatr; 2000 Jun; 136(6):711-3. PubMed ID: 10905886
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of ursodeoxycholic acid on HCV replication in subtyped chronic hepatitis C.
    Mohler M; Seipp S; Tox U; Stremmel W; Theilmann L; Goeser T
    Dig Dis Sci; 1996 Jun; 41(6):1276-7. PubMed ID: 8654164
    [No Abstract]   [Full Text] [Related]  

  • 17. Liver fibrosis assessment by transient elastography in hepatitis C patients with normal alanine aminotransferase.
    Moreno-Otero R; Trapero-Marugan M; Mendoza J
    Gut; 2006 Jul; 55(7):1055-6. PubMed ID: 16766767
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of ursodeoxycholic acid treatment for cholestasis in liver transplant recipients.
    Rafael E; Duraj F; Rudström H; Wilczek H; Ericzon B
    Transplant Proc; 1995 Dec; 27(6):3501-2. PubMed ID: 8540069
    [No Abstract]   [Full Text] [Related]  

  • 19. Variations of zinc in acute and chronic hepatitis (preliminary data).
    Tănăsescu C; Chirulescu C; Chirulescu Z
    Rom J Intern Med; 1996; 34(1-2):79-84. PubMed ID: 8908634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: a multicenter, prospective, randomized, controlled trial in Japan.
    Yano M; Hayashi H; Yoshioka K; Kohgo Y; Saito H; Niitsu Y; Kato J; Iino S; Yotsuyanagi H; Kobayashi Y; Kawamura K; Kakumu S; Kaito M; Ikoma J; Wakusawa S; Okanoue T; Sumida Y; Kimura F; Kajiwara E; Sata M; Ogata K
    J Gastroenterol; 2004 Jun; 39(6):570-4. PubMed ID: 15235875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.